Ectopic Expression of Axin Blocks Neuronal Differentiation of Embryonic Carcinoma P19 Cells*

Jungmook LyuDagger , Frank Costantini§, Eek-hoon Jho||, and Choun-ki JooDagger **

From the Dagger  Department of Ophthalmology, Catholic University of Korea, Seoul 137-040, Korea, the § Department of Genetics and Development, Columbia University, New York, New York 10032, and the  Department of Life Science, The University of Seoul, Seoul 130-743, Korea

Received for publication, January 19, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Axin regulates Wnt signaling through down-regulation of beta -catenin. To test the role of Wnt signaling in neuronal differentiation, embryonal carcinoma P19 cells (P19 EC), which can be stimulated to differentiate into a neuron-like phenotype in response to retinoic acid (RA), were used. Reverse transcription-PCR and Western blot analysis showed that Axin is expressed in undifferentiated cells, whereas the level is clearly reduced during RA-induced neuronal differentiation. Interestingly, Axin levels were not reduced during endodermal differentiation of P19 EC cells and F9 EC cells by RA, suggesting that the reduction of the Axin level is a specific property of neuronal differentiation. Western analysis showed that the cytoplasmic level of beta -catenin increased during neuronal differentiation of P19 EC cells. Indirect immunofluorescence with beta -catenin antibody showed that the localization of beta -catenin was changed from membrane in undifferentiated cells to nuclei in neuronal P19 EC cells. Induced expression of Axin during endodermal and early neuronal differentiation, using the Tet-On system, did not block normal differentiation. However, maintenance of the Axin level blocked neuronal differentiation and inhibited expression of a neuron-specific marker protein, beta III-tubulin. Also, ectopic induction of a beta -catenin signaling inhibitor, ICAT, inhibited expression of beta III-tubulin. In contrast, addition of Wnt-3A-conditioned medium during the neuronal differentiation period enhanced the expression of beta III-tubulin. Overall, our data show that Wnt-3a/canonical beta -catenin signaling through the down-regulation of Axin may play an important role in neuronal differentiation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Wnt signaling pathway has critical roles in embryonic development, differentiation, and tumorigenesis (1-4). Currently, 19 Wnt genes have been identified in humans and most of them have homologs in other organisms (5). The tightly controlled temporal and spatial expression patterns of Wnt genes have implied that different Wnts have specific roles in embryonic development, and ablation of specific Wnt genes in mice have shown that this is true (6, 7). In particular, targeted inactivation of Wnt-1, Wnt-3a, or Wnt-7a in mice suggest that they have critical roles in neural development and neural cell fate determination (8-10).

Wnt genes encode secreted glycoproteins that signal through the cell surface receptor Frizzled, which has at least 10 orthologs in mammals, and other coreceptors (for a review, see Ref. 11). Recent data suggest that heterotrimeric G-proteins are involved in the signaling between receptors and downstream pathways (12). Upon binding of Wnts to Frizzled, Dvls are activated and antagonize the beta -catenin degradation complex, which contains adenomatous polyposis coli, GSK-3beta ,1 and Axin, as well as other proteins (13-25). beta -Catenin that escapes from the degradation complex enters into nuclei and interacts with Tcf/LEF factors to regulate expression of downstream target genes (26-34).

Axin was originally identified by an insertional mutation in transgenic mice (AxinTg1), which caused developmental defects similar to those in mice carrying spontaneous mutations at the genetic locus called Fused (35, 36). Ectopic expression of Axin in Xenopus embryos showed that Axin blocked embryonic axis formation by inhibition of the canonical Wnt/beta -catenin pathway (37), a finding that has been confirmed by genetic analysis in Drosophila (38, 39). The accumulating data have shown that Axin acts as a scaffolding protein, containing several domains that interact with adenomatous polyposis coli, GSK-3beta , CKI, beta -catenin, and other proteins (13-25). In the absence of a Wnt signal, Axin itself is phosphorylated and enhances phosphorylation of beta -catenin by GSK-3beta by bringing those proteins together, and the ubiquitin-proteasome-mediated pathway leads phosphorylated beta -catenin to degradation (26-30). However, antagonizing GSK-3beta activity upon binding of Wnts to Frizzled leads to an increase in hypophosphorylated Axin, which has lower affinity to interact with beta -catenin. This results in the release of hypophosphorylated beta -catenin from the degradation complex (40, 41). The released hypophosphorylated beta -catenin is accumulated in the cytoplasm, translocated into nuclei, and then interacts with Tcf/LEF factors to regulate downstream target gene expression. Currently, about 50 target genes have been identified. The known function of several identified target genes explains some of the phenotypes that are caused by abnormal Wnt signaling. For example, induction of c-myc or cyclin D1 expression by Wnt signaling causes abnormal cell proliferation and results in tumors, whereas ectopic Xenopus axis induction by the injection of Wnts is due to enhanced expression of the dorsalizing homeobox gene siamois, brachyury gene, and others (42-45).

Among the diverse biological roles of Wnts, their involvement in neural differentiation has been studied due to prominent expression of several Wnts in the developing central nervous system (6, 7). Indeed, absence of Wnt-1 and Wnt-3a leads to abnormal populations of dorsal interneurons, implying that Wnt signaling has a role in the determination of neuronal cell fate (46). An elegant finding by Hall et al. (10), that secretion of Wnt-7a from postsynaptic granule cell neurons remodels the axons and growth cones of developing mossy fibers, is another good example for involvement of Wnt signaling in neuronal differentiation. However, it has not been shown that Wnt signaling plays any autocrine role in neurite extension.

The pluripotent P19 embryonal carcinoma (EC) cell line has been used as a model system to study neuronal differentiation, because these cells can be easily differentiated into neuronal cells that form neurite-like structures upon simple retinoic acid treatment (47, 48). It has been reported that the expression of diverse Wnts are regulated during neuronal differentiation, and it has therefore been suggested that different Wnts may have roles in this process (49). However, although many Wnts display a dynamic expression pattern during the neuronal differentiation of P19 cells, so far only Wnt1 has been tested for a potential role in this process, and it remains unknown whether endogenous canonical beta -catenin signaling is involved in the neuronal differentiation of P19 cells (49, 50).

We show here that Axin is down-regulated and that beta -catenin accumulates in the cytoplasm and the nucleus, during the neuronal differentiation of P19 cells. These data imply that canonical beta -catenin signaling is involved in the neuronal differentiation of P19 cells. To test the significance of canonical beta -catenin signaling for this process, the expression of Axin was induced during RA-induced neuronal differentiation, using the Tet-On-inducible system (51, 52). This treatment blocked the formation of neurite-like structures. In contrast, neuronal differentiation of P19 cell was enhanced in the presence of Wnt-3a-conditioned media. Overall, our data lead us to conclude that Wnt-3a/canonical beta -catenin signaling through the down-regulation of Axin may play an important role in neural differentiation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture and Differentiation-- P19 embryonal carcinoma (EC) cells (obtained from ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum (FBS, HyClone Laboratories Inc.), 100 units/ml penicillin, 100 µg/ml streptomycin, and 2 mM L-glutamine (Invitrogen), in humidified 5% CO2. To induce neuronal differentiation by P19 EC cells, they were aggregated in bacterial-grade Petri dishes with 1 µM all-trans-retinoic acid (Sigma) at a density of 1 × 105/ml. After 4 days, aggregates were dissociated by 0.25% trypsin-0.53 mM EDTA (Invitrogen), and re-plated in poly-L-lysine-coated tissue culture dishes and then allowed to differentiate 6 more days. For endodermal differentiation, P19 and F9 cells were cultured with 10 and 100 nM RA, respectively, for 4 days.

Wnt-3a-expressing L cells (kindly provided by Dr. Roel Nusse, Stanford University) were cultured in DMEM containing 10% FBS and 200 µg/ml G418 (Invitrogen). For preparation of Wnt-3a-conditioned medium (CM), the Wnt-3a-expressing L cells were grown in serum-free DMEM in humidified 5% CO2, and Wnt-3a CM was harvested after 24 h. Wnt-3a CM was concentrated to 30 times by using Centricon (Millipore). P19 cells were incubated with 10× Wnt-3a CM supplemented with 10% FBS.

Immunochemical Staining-- For immunofluorescent labeling, cells were fixed with 4% paraformaldehyde and washed in phosphate-buffered saline (PBS), then permeabilized with 0.05% Triton X-100 in PBS. The fixed cells were incubated with blocking solution (1% normal goat serum (Jackson ImmunoResearch Laboratories, Inc.), 2% bovine serum albumin (Sigma) in PBS) for 1 h. The cells were then incubated overnight at 4 °C with mouse monoclonal anti-SSEA-1 (Development Studies Hybridoma Bank), anti-beta III-tubulin (BAbCO), anti-MAP2 (Sigma), anti-beta -catenin, or anti-E-cadherin antibodies (Transduction laboratories). After a rinse with PBS, the cells were incubated with rhodamine, or fluorescein isothiocyanate-conjugated (Jackson ImmunoResearch Laboratories) secondary antibodies at room temperature for 1 h, mounted, and examined using a fluorescence microscope (Zeiss).

Northern Blot and RT-PCR-- Total RNA was isolated using TRIzol (Invitrogen) from undifferentiated or differentiated P19 cells at different time periods. For Northern blot analysis, ~20 µg of total RNA was separated on a 1.2% formaldehyde-agarose gel and transferred to NC membranes (Amersham Biosciences) by using a TurboBlotter kit (Schleicher & Schuell). The inserts for the preparation of probes for mouse Wnt-1, Wnt-3a, and Wnt-5a were generated by PCR, using the pLNCX/Wnt-1, pLNCX/Wnt-3a, and pLNCX/Wnt-5a plasmid DNA (kind gift from Dr. Jan Kitajewski, Columbia University) as templates with primers derived from sequences in GenBankTM. The insert for the mouse beta -actin was obtained by RT-PCR with total RNA of P19 EC cells. The sequences of all PCR products were confirmed by automated sequencing. All probes were labeled with [alpha -32P]dCTP using a Random Primed DNA Labeling kit (Roche Molecular Biochemicals) and hybridized to the membrane with ExpressHyb solution (Clontech) according to the manufacturer's protocol. All Northern blots were stripped and hybridized to beta -actin cDNA probe for even RNA loading control.

The following primers were used for PCR: for Wnt-1, 5'-CAGTAGTGGCCGATGGTG-3' and 5'-ATCGATGTTGTCACTGC-3'; for Wnt-3a, 5'-TAGTGCTCTGCAGCCTGAA-3' and 5'-CCACAGATAGCAGCTGAT-3'; for Wnt-5a, 5'-ATTGGAATATTAAGCCCG-3' and 5'-GTGACCATAGTCGATGTT-3'; for beta -actin, 5'-AGGCCAACCGCGAAGATGACC-3' and 5'-GAAGTCCAGGGCGACGTAGCAC-3'; for Axin, 5'-CAGGGTTTCCCCTTGGACC-3' and 5'-GGTCAAACATGGCAGGATC-3'; and for ICAT, 5'-GAATTCGATGAACCGCGAGGGAGCAC-3' and 5'-CTCGAGCTACTGCCTCCGGTCTTCCGT-3'.

Western Blot-- Cells were lysed in lysis buffer containing 20 mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.1% SDS, 0.5% deoxycholic acid, 10% glycerol, 100 mM sodium orthovanadate, and protease inhibitor mixture (1 mM EDTA, 1 mM PMSF, 5 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin). Brains of 13.5 dpc Balb/c mouse embryos and 1-month-old postnatal mice were dissected and homogenized in lysis buffer (20 mM Tris-HCl (pH 7.4), 1% Triton X-100, 10% glycerol, 150 mM NaCl, 1 mM EDTA, 20 mM NaF, 2 mM Na3VO4, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin). Homogenates were clarified by centrifugation at 14,000 × g for 15 min at 4 °C, and total extracts were obtained in the supernatant. Protein concentration was measured using Bradford reagent (Bio-Rad). About 20 µg of lysate was subjected to SDS-PAGE, and Western blot using following antibodies. Mouse monoclonal antibodies for c-myc (for the detection of myc-tagged Axin, Oncogene), beta III-tubulin (BAbCO), MAP2, actin, alpha -tubulin (Sigma), GFP (Clontech), GSK-3beta , beta -catenin antibodies (Transduction Laboratories), and a rabbit polyclonal antibody for Axin (kind gift from Dr. Paul Polakis, Genentech Inc.) were used to detect the corresponding proteins. Peroxidase-conjugated sheep anti-mouse and donkey anti-rabbit secondary antibodies (Sigma) were used, and then the proteins were detected by using an enhanced chemiluminescence (ECL) reagent (Santa Cruz Biotechnology, Inc.).

Preparation of Cytoplasmic Fraction-- Cells were washed twice in PBS and scraped in physiological buffer containing 10 mM Tris-HCl (pH 7.4), 140 mM NaCl, 5 mM EDTA, 2 mM dithiothreitol, 0.5 mM PMSF, 2 µg/ml aprotinin, 1 µg/ml leupeptin. Cells were lysed by 30 strokes in a chilled Potter-Elvehjem homogenizer (Wheaton) at 4 °C. The lysates were centrifuged at 500 × g for 10 min to remove unbroken cells and nuclei. The cleared lysates were subject to ultracentrifugation at 100,000 × g for 90 min at 4 °C. The supernatants were collected as the cytoplasmic fraction. Protein concentration of the cytoplasmic fraction was measured by using Bradford reagent (Bio-Rad).

Construction of Plasmids-- To construct pBI-EGFP-Axin, pCS2-MT-mAxin (125-956) was digested with ClaI and NotI, and both ends were filled-in with Klenow fragment (Invitrogen). The 3-kb fragment was inserted into pBI-EGFP (Clontech), which was digested with NheI and blunted with Klenow fragment. The SpeI and HindIII digested fragment of the pTet-On (Clontech) was replaced with SpeI/HindIII fragment of the pUHDrtTA2S-M2 (kind gift from Dr. Wolfgang Hillen, Erlangen University (52)) to construct CMV-rtTA2S-M2, which has a neomycin resistance gene and improved version of rtTA. Mouse ICAT cDNA was cloned by RT-PCR using total mouse RNA as template from a published sequence (53). Cloned ICAT cDNA was inserted into the pCS2-MT vector (13) for myc tagging on the amino terminus (pCS2-MT-ICAT). pBI-EGFP-ICAT was constructed from pCS2-MT-ICAT with the same methods that were described for the generation of pBI-EGFP- Axin.

Generation of Stable Cell Lines and Induction by Doxycycline-- P19 cells were cotransfected with the CMV-rtTA2S-M2 and pBI-EGFP-Axin, or pBI-EGFP using the Lipofectin reagent (Invitrogen) according to the manufacture's protocol. Two days after transfection, transfectants were subcultured and selected in culture media supplemented with 400 µg/ml G418. Each selected clone was analyzed by fluorescence microscopy and Western blot analysis. To induce expression of Axin or green fluorescent protein (GFP), P19 cells were treated with 500 ng/ml doxycycline (Sigma).

Luciferase Assay-- To measure the inhibitory effect of an ICAT-expressing construct on beta -catenin/Tcf signaling, we performed luciferase assays as described previously (40).

XTT Assay-- Cell viability was analyzed using an XTT cell proliferation kit (Roche Molecular Biochemicals) according to the manufacturer's instructions. P19 cells exposed to RA during aggregation were trypsinized, and 5 × 103 cells were re-plated onto 96-well plates. Cells were incubated with or without Dox for 6 days, and tetrazolium salt XTT was added. The plates were incubated further for 4 h at 37 °C, and the optical density at 450 nm (A450) was measured with a spectrophotometer.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Differential Expression of Wnt Signaling Components during Neuronal Differentiation of P19 EC Cells-- P19 embryonal carcinoma (EC) cells can be differentiated into neuronal cells upon retinoic acid (RA) treatment during aggregation followed by plating on tissue culture plates (47, 48). This process can be detected with the neuron-specific marker proteins, beta III-tubulin and MAP2 (microtubule-associated protein 2) (Fig. 1A). Two days after plating, neurite-like structures began to appear, and after 6 days these structures were obvious and clearly detected by immunochemical staining with beta III-tubulin and MAP2 antibodies. It has been shown that several Wnts were differentially expressed during neuronal differentiation of P19 EC cells (49). We observed a similar pattern of Wnt expression during neuronal differentiation (Fig. 1B). Wnt-1 mRNA is transiently expressed upon plating on tissue culture plates after aggregation and the early stages of neuronal differentiation have occurred. Interestingly, during the later stages of differentiation (4 and 6 days after plating), the level of Wnt-1 mRNA expression rapidly diminished, whereas the expression of Wnt-3a was induced. In contrast to either Wnt-1 or Wnt-3a, the level of Wnt-5a increases steadily during differentiation. These observations suggest that Wnt-1, Wnt-3a, and Wnt-5a may have different roles in P19 EC cell differentiation. The occurrence of proper neuronal differentiation was confirmed by Western blot analysis using anti beta III-tubulin and MAP2 antibodies (Fig. 1C).


View larger version (85K):
[in this window]
[in a new window]
 
Fig. 1.   Differential Wnt expression during neuronal differentiation of P19 embryonal carcinoma (EC) P19 EC cells. A, to induce neuronal differentiation, P19 EC cells were plated on bacterial Petri dishes and allowed to aggregate for 4 days in the presence of 1 µM RA and then re-plated on tissue culture dishes. 2 and 6 days after plating, the cells were stained with anti-beta III-tubulin or MAP2 antibodies. Rhodamine-conjugated secondary antibody was used to detect the expression of beta III-tubulin (b and c, phase contrast (PC); e and f, indirect immunofluorescence (IF)). Fluorescein isothiocyanate-conjugated secondary antibody was used to visualize the expression of MAP2 (h and i, PC; k and l, IF). Undifferentiated cells (UD) are shown as a control (a and g, PC; d and j, IF). B, Northern blot analysis of several Wnts during neuronal differentiation. At an early stage of neuronal differentiation the Wnt-1 level is transiently elevated. At a later stage, Wnt-1 is down-regulated while the Wnt-3a level is up-regulated. The Wnt-5a level increases steadily throughout differentiation. C, induction of beta III-tubulin and MAP2, as revealed by Western blot analysis, confirms the proper neuronal differentiation of P19 EC cells.

It was shown that Axin is down-regulated upon Wnt-3a treatment of C57MG and L cells (41, 54). Because the endogenous Wnt-3a level increased during neuronal differentiation of P19 EC cells, we examined the levels of Axin mRNA (Fig. 2A) and protein (Fig. 2B), and found that they were both down-regulated during neuronal differentiation (3.2 ± 0.9-fold reduction in protein level for the 6-day-differentiated compared with undifferentiated samples (n = 3)). We predicted that down-regulation of Axin might lead to stabilization of cytoplasmic beta -catenin. As shown in Fig. 2C, cytoplasmic beta -catenin is steadily accumulated during neuronal differentiation (4.1 ± 1.2-fold induction in undifferentiated versus in 6-day-differentiated samples (n = 3)), whereas the actin and total beta -catenin levels are unchanged. It is well accepted that accumulated cytoplasmic beta -catenin is translocated into nuclei to regulate the expression of downstream target genes. Immunochemical staining with anti beta -catenin antibody revealed that beta -catenin is mainly localized in the nuclei of differentiated cells, in contrast to its membrane localization in undifferentiated cells (Fig. 2D). These data suggest that down-regulation of Axin and induction of beta -catenin signaling is important for neuronal differentiation. To test whether the down-regulation of Axin occurs in vivo as well as during P19 EC cell differentiation, the Axin level was compared in the brains of 13.5 dpc mouse embryos (which contain many undifferentiated neuronal precursor cells) versus brains of 1-month-old postnatal mice (which contain more differentiated neurons). The level of the neuron-specific marker beta III-tubulin was increased during that period, as shown by others (55), whereas the Axin level was reduced (Fig. 2E). RA treatment of F9 EC, or treatment of P19 EC cells with a low concentration of RA (10 nM), can lead to endodermal differentiation (48). During endodermal differentiation of both cell lines, as monitored by morphological changes (data not shown) the Axin level was not changed (Fig. 2F). These in vivo and in vitro data imply that the down-regulation of Axin occurs specifically during neuronal differentiation but not endodermal differentiation.


View larger version (51K):
[in this window]
[in a new window]
 
Fig. 2.   Axin mRNA and protein levels are reduced, whereas the cytoplasmic beta -catenin level is increased during neuronal differentiation. RT-PCR (A) and Western blot analysis (B) illustrate that the Axin level is reduced while the beta III-tubulin level is increased during neuronal differentiation. An equal level of alpha -tubulin was used for the loading control. C, the level of beta -catenin in the cytoplasm is induced during neuronal differentiation, whereas the total beta -catenin level is unchanged. Actin was used as a loading control. D, the localization of beta -catenin was changed from plasma membrane in undifferentiated P19 EC cells to nuclei in neuronally differentiated cells. Bar, 50 µm. E, the level of Axin protein is lower in the brain of a 1-month-old mouse than in 13.5 dpc embryonic brain, whereas the expression pattern of a neuronal marker, beta -III tubulin, is increased. F, axin protein level is not reduced during endodermal differentiation of P19 EC and F9 embryonal carcinoma cells.

Inducible, Ectopic Expression of Axin in RA-treated P19 Cells Blocks Formation of Neurite-like Structures-- To test whether the reduction in Axin levels is important for neuronal differentiation, we used the Tet-On-inducible system to force the continued expression of Axin in RA-treated P19 cells. Axin was cloned into the bi-directional pBI-EGFP vector allowing EGFP to be used to infer the level of Axin expression in the transfected cells (Fig. 3A). Cells transiently cotransfected with CMV-rtTA and pBI-EGFP-Axin showed clear induction of Axin and EGFP after Dox treatment (Fig. 3B), Axin was clearly induced in pBI-EGFP-Axin-transfected clones after 1 day of Dox treatment and disappeared in a day after removal of Dox, whereas the EGFP level was maintained (Fig. 3C), possibly reflecting an intrinsic difference in the stability of the two proteins in these cells. The rapid reduction in Axin levels after withdrawal of Dox was useful, in that it allowed us to induce Axin expression in transient manner.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 3.   Use of the Tet-On-inducible system to express Axin. A, diagram for the scheme of the Tet-On-inducible system. B, induction of Axin and EGFP by Dox treatment of P19 EC cells, which were stably transfected with pBI-EGFP/CMV-rtTA or pBI-EGFP-Axin/CMV-rtTA. C, Axin was detectable after 1 day of induction by Dox and lost within 1 day after removal of Dox, whereas EGFP was still detectable 2 days after removal of Dox. Actin was used for the loading control.

P19 cell clones stably transfected with pBI-EGFP-Axin/CMV-rtTA2S-M2 or pBI-EGFP/CMV-rtTA2S-M2 were treated with Dox. This resulted in clear induction of myc-tagged Axin in pBI-EGFP-Axin/CMV-rtTA2S-M2 (Fig. 4A, lanes 2 and 4). In the absence of RA treatment (i.e. in undifferentiated cells), there was no apparent change in the level of beta -catenin following Axin induction (Fig. 4B, lanes 1 and 2), which might be due to a very low level of cytoplasmic beta -catenin in undifferentiated P19 cells. When the P19 cells were induced to differentiate with RA, there was an increase in cytoplasmic beta -catenin (Fig. 4B, lanes 1 and 3), consistent with the data of Fig. 2C. However, this accumulation of cytoplasmic beta -catenin was reduced by the Dox-induced expression of Axin (Fig. 4B, lanes 3 and 4). Interestingly, the expression of Axin in these cells also blocked the induction of the neuron-specific marker beta III-tubulin (5.2 ± 1.4-fold reduction (n = 4), Fig. 4A, lanes 3 and 4). We took advantage of the bi-directional inducible vector system to examine morphological changes in pBI-EGFP-Axin/CMV-rtTA2S-M2- or pBI-EGFP/CMV-rtTA2S-M2-expressing stable cell clones. When pBI-EGFP/CMV-rtTA2S-M2-expressing stable cell clones were aggregated and differentiated by RA treatment, neurite-like structures formed (arrows in Fig. 4C, top panel, 76.3 ± 5.5% of EGFP-positive cells). However, the Dox-induced expression of Axin in pBI-EGFP-Axin/CMV-rtTA2S-M2-expressing stable cell clones significantly reduced the formation of those structures (Fig. 4C, bottom panel, 34.0 ± 13.5% of EGFP-positive cells).


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 4.   Induction of Axin blocks neuronal differentiation of P19 EC cells. A and B: lanes 1 and 2, P19 EC cells stably transfected with CMV-rtTA2SM2 and pBI-EGFP-Axin were treated with Dox for 4 days (lane 2) without RA. beta III-tubulin was not induced, and the cytoplasmic beta -catenin level was not changed by the forced expression of Axin. Lanes 3 and 4, P19 EC cells were aggregated in the presence of RA and re-plated on tissue culture dishes without (lane 3) or with Dox (lane 4) for 4 days. The induction of cytoplasmic beta -catenin (lane 4 in B), and the neuronal marker beta III-tubulin (lane 4 in A) was clearly reduced. C, induction of Axin blocks formation of the neurite-like structures (bottom panel), whereas P19 EC clones carrying the control vector pBI-EGFP and CMV-rtTA formed neurites in the presence of Dox (arrows in top panel). D, XTT assay for the measurement of viable cells. pBI-EGFP/CMV-rtTA- or pBI-EGFP-Axin/CMV-rtTA-expressing stable cell lines were aggregated and differentiated in the presence of different Dox concentrations. Six days after differentiation, tetrazolium salt XTT was added to those cultures, incubated for 4 h and measured for formation of XTT formazan.

Previously we and others have shown that overexpression of Axin caused apoptosis in transgenic mice and certain cell lines (56, 57). However, we could not see any obvious cell death after transient induction of Axin in undifferentiated P19 cells (data not shown). We also tested whether the failure of Dox-induced pBI-EGFP-Axin/CMV-rtTA2S-M2 cells to form neurite-like structures upon RA treatment was due to excessive cell death. pBI-EGFP-Axin/CMV-rtTA2S-M2- or pBI-EGFP/CMV-rtTA2S-M2-expressing stable cell clones were aggregated and differentiated in the presence of RA and different concentrations of Dox. The XTT assay revealed no clear difference in viable cell numbers between pBI-EGFP-Axin/CMV-rtTA2S-M2 and pBI-EGFP/CMV-rtTA2S-M2 clones upon ectopic Axin induction (Fig. 4D). Therefore, the effect of Axin on neuronal differentiation of P19 cells is not due to cell death.

Ectopic Induction of a beta -Catenin Signaling Inhibitor, ICAT, Inhibited Expression of beta III-tubulin during Neuronal Differentiation of P19 Cells-- To determine whether reduction of beta -catenin signaling is the main reason for the inhibition of neuronal differentiation when Axin is induced, we used a different approach to block beta -catenin signaling. ICAT is known to inhibit Wnt/beta -catenin signaling by blocking the interaction between beta -catenin and Tcf/LEF factors (53, 58). We tested whether ectopic induction of ICAT acted similarly to Axin. Western analysis showed that the ICAT level was maintained consistently throughout neuronal differentiation (data not shown). Luciferase reporter assay by transient transfection of ICAT plasmid suggested that our myc-tagged ICAT works as an inhibitor of Wnt/beta -catenin signaling (Fig. 5, A-C). Myc-tagged ICAT was cloned into pBI-EGFP vector (Fig. 5A), and P19 cell clones stably transfected with pBI-EGFP-ICAT/CMV-rtTA2S-M2 were treated with Dox. Induction of myc-ICAT resulted in the reduction of neuron-specific marker beta III-tubulin (2.3 ± 0.3-fold (n = 3)) compared with control cells in which neuronal differentiation was induced by RA in the absence of Dox (Fig. 5D, lanes 3 and 4). This result supports our conclusion that the blocking of neuronal differentiation by ectopic Axin induction is mediated through the canonical Wnt pathway.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 5.   Induction of ICAT down-regulates the expression of the neuronal marker beta III-tubulin. A, diagram of pCS2-MT-ICAT and pBI-EGFP-ICAT constructs. B, expression of myc-GFP and myc-ICAT after transient transfection. C, luciferase reporter assay after transfection of 293T cells with indicated plasmids showed that myc-ICAT blocked beta -catenin mediated induction of Tcf signaling. D: lanes 1 and 2, P19 EC cells stably transfected with CMV-rtTA2SM2 and pBI-EGFP-ICAT were treated with Dox for 4 days (lane 2) without RA. Lanes 3 and 4, P19 EC cells were aggregated in the presence of RA and re-plated on tissue culture dishes without (lane 3) or with Dox (lane 4) for 4 days. The induction of the neuronal marker beta III-tubulin (lane 4 in D) was clearly reduced upon induction of myc-ICAT.

The Later Phase of Neuronal Differentiation by P19 Cells Is the Sensitive Period for Blockage by Axin-- The ability to transiently induce the expression of Axin by a short treatment with Dox (Fig. 3C) allowed us to examine the stage of P19 neuronal differentiation that is sensitive to Axin expression. Neuronal differentiation of pBI-EGFP-Axin/CMV-rtTA2S-M2 cells (with no Dox treatment) resulted in induction of beta III-tubulin expression (Fig. 6, lanes 1 and 2), as shown above for P19 cells (Fig. 2). Dox-induced expression of Axin during the entire 10-day culture period caused a reduction in beta III-tubulin induction (Fig. 6, lane 7). However, Dox-induced expression of Axin during the first 4 days (aggregation), followed by withdrawal of Dox for the next 6 days (differentiation), had no effect on beta III-tubulin expression (Fig. 6, compare lanes 2 and 6). Axin expression was eliminated within 2 days after withdrawal of Dox (Fig. 6, lane 4). These data suggest that induction of Axin during the 4-day aggregation period is not sufficient to block neuronal differentiation. Induction of Axin for the first 6 days has no greater effect on beta III-tubulin expression than does induction for the first 4 days (Fig. 6, compare lanes 4 and 5). In Fig. 4 (A and C), neuronal differentiation was blocked when Axin was induced only during the neuronal differentiation period and not during aggregation. Overall, these experiments suggest that the later stages of RA-induced neuronal differentiation by P19 EC cells are sensitive to the level of Axin expression.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 6.   The late stage of neuronal differentiation is sensitive to the inhibitory effects of Axin. Proteins were isolated from pBI-EGFP-Axin/CMV-rtTA-expressing stable cell clones after different periods of Dox treatment and withdrawal. Lane 1, undifferentiated cells; lane 2, cells differentiated for 10 days without Dox; in lanes 3-7, Dox was added during the 4-day aggregation period, and then either continued or withdrawn at different times after plating; lane 3, 4 days Dox; lane 4, 4 days Dox plus 2 days withdrawal; lane 5, 6 days Dox; lane 6, 4 days Dox plus 6 days withdrawal; lane 7, 10 days Dox. The level of beta -III tubulin was used to monitor neuronal differentiation. Constitutive induction of Axin during later neuronal differentiation blocked the induction of beta -III tubulin (lanes 6 and 7).

Ectopic Expression of Axin Has No Effect on the Initiation of Differentiation but Blocks the Maturation of Neurite-like Structures-- We have shown that ectopic induction of Axin blocks neuronal differentiation, such as the formation of neurite-like structures. Next, we tested whether induction of Axin blocks other differentiation processes. It is known that the level of the embryonic antigen SSEA-1 and E-cadherin are reduced upon RA-induced differentiation of P19EC cells (59, 60). Undifferentiated pBI-EGFP-Axin/CMV-rtTA2S-M2 cell clones, and those induced to differentiate in the absence or presence of Dox, were immunochemically stained with antibodies specific for SSEA-1, beta III-tubulin, MAP-2, and E-cadherin. Consistent with the above data, the Dox-induced expression of Axin greatly reduced the expression of the neuronal markers beta III-tubulin and MAP-2 (Fig. 7; compare with Fig. 4). However, this treatment had no effect on the down-regulation of SSEA-1 or E-cadherin (Fig. 7). These data suggest that ectopic induction of Axin does not block the initiation of differentiation by P19 cells but blocks a later step in the neuronal differentiation pathway.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 7.   Induced expression has no significant effect on the initiation of differentiation but blocks formation of neurite-like structures. pBI-EGFP-Axin/CMV-rtTA-containing P19 EC clones were differentiated by RA treatment in the presence or absence of Dox. Cells were stained with either markers for undifferentiated EC cells (SSEA-1 and E-cadherin) or neuronal markers (beta -III tubulin and MAP2) and rhodamine-conjugated secondary antibodies. Regardless of Axin induction, markers for undifferentiated EC cells were lost upon RA treatment (a, e, and i for SSEA-1; d, h, and l for E-cadherin). Neuronal differentiation markers beta -III tubulin and MAP2 were barely detectable in the presence of Axin induction (b, f, and j for beta -III tubulin; c, g, and k for MAP2).

Wnt3a Enhances Neuronal Differentiation of P19 EC Cells-- Smolich and Papkoff (49) showed that overexpression of Wnt-1 could not induce normal neuroectodermal differentiation of P19 EC cells, although it could enhance certain aspects of that process. They suggested that correct timing of Wnt expression is necessary for proper neural differentiation. Wnt expression patterns, as shown by others (49) and in Fig. 1B, suggest that Wnt-3a may have a more important role than Wnt-1 in late neuronal differentiation. Because Wnt-3a is induced during the late neuronal differentiation period, we tested whether Wnt-3a could enhance neuronal differentiation. Consistent with several published reports, incubation of P19 EC cells with Wnt-3a-conditioned media (CM) caused a reduction in the Axin level and an increase in the cytoplasmic beta -catenin level (Fig. 8). Incubation of undifferentiated P19 EC cells in the presence of Wnt-3a CM did not induce expression of the neuronal marker protein beta III-tubulin. These data suggest that Wnt-3a does not have the ability to induce neuronal differentiation. However, when P19 EC cells were aggregated and differentiation was induced by RA in the presence of Wnt-3a-conditioned media, the level of beta III-tubulin was obviously enhanced (Fig. 8). These data suggest that Wnt-3a signaling through the down-regulation of Axin and up-regulation of cytoplasmic beta -catenin may play an important role in neural differentiation.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 8.   Wnt-3a-conditioned medium down-regulates Axin level and results in clear induction of the neuronal differentiation marker beta -III tubulin. Undifferentiated P19 EC cells were grown in control or Wnt-3a-conditioned media (CM). Incubation with Wnt-3a CM led to down-regulation of Axin and induction of cytoplasmic beta -catenin. However, it did not induce beta -III tubulin expression in undifferentiated P19 EC cells (lanes 1 and 2). P19 EC cells were aggregated for 4 days in the presence of 1 µM RA and then re-plated on tissue culture dishes in the presence of control or Wnt-3A CM for 4 more days. The Axin level was reduced in cells differentiated in the presence of Wnt-3a CM and the level of neuronal differentiation marker beta -III tubulin was clearly enhanced.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

While the evidence for the significance of Wnt signaling in overall neural development was accumulated in many model organisms, such as in mouse, zebrafish, and frog, specific roles of different Wnts in neuronal cell differentiation were not well studied. Only a few studies, which revealed determination of neuronal cell fate by Wnt3a and regulation of presynaptic axon structure by Wnt7a, have been published (10, 46). The involvement of Wnt signaling in the neuronal differentiation of P19 embryonic carcinoma cells has been suggested by the differential expression of various Wnts during that process (49). Here, we provide evidence for the role of Wnt/canonical beta -catenin signaling specifically in neurite extension/maturation. We report that Axin, a negative regulator of the canonical Wnt signaling pathway, is down-regulated while the beta -catenin level is increased during neuronal differentiation of P19 cells. Furthermore, the forced expression of either Axin or ICAT, a beta -catenin signaling inhibitor, during the neuronal differentiation process resulted in blockage of neurite formation and the induction of the neuron-specific marker beta III-tubulin. In addition, the enhanced expression of beta III-tubulin after treatment with Wnt3A-conditioned medium suggests that Wnt/beta -catenin signaling has a positive role in neuronal differentiation.

Several groups have used P19 cells to test the role of Wnt signaling in neuronal differentiation by simple overexpression of specific Wnts (49, 50). However, the dynamic changes in the expression of diverse Wnts during neuronal differentiation (Fig. 1B) lead us to test the significance of canonical Wnt signaling by blocking it, through the induced expression of Axin, rather than by overexpression of specific Wnts. Although Wnt1 and Wnt3a show similar spatial and temporal expression patterns in vivo and are considered to belong to the same group of Wnts, which signal through beta -catenin, the temporal expression of these two Wnts do not seem to overlap during neuronal differentiation of P19 cells (Fig. 1B). These differing expression profiles imply that Wnt1 and Wnt3a may have different roles in the regulation of the neuronal differentiation process, which might account for the failure of Wnt1 to induce normal differentiation when overexpressed in P19 cells (49). Recently emerging data suggest that Ca2+ signaling is involved in learning and memory, and a non-canonical protein kinase C/Ca2+ pathway is also important in transducing certain Wnt signals (for review, see Refs. 2 and 61). The steady increase of Wnt5a, which is believed to regulate the protein kinase C/Ca2+ pathway, during neuronal differentiation (Fig. 1B) suggests a role for non-canonical Wnt signaling in neuronal differentiation of P19 cells (although it was not examined in the current work).

We found that the Wnt1 and Wnt3a mRNA levels are increased and beta -catenin is accumulated in nuclei during neuronal differentiation (Fig. 2). It is generally considered that Wnt1 and 3a have mitogenic activity rather than a role in differentiation. However, recently it has been shown that Wnt3a/beta -catenin signaling is necessary and sufficient for myogenic differentiation in P19 cells, and Wnt1 is also known to have role in melanocyte expansion and differentiation during mouse embryogenesis (62, 63). This raises the interesting question of how the same beta -catenin accumulation in nuclei directs two opposite outputs: enhancement of mitogenic activity and differentiation.

To determine whether the blockage of neuronal differentiation by ectopic Axin induction was due to down-regulation of canonical beta -catenin signaling, rather than activation other signaling pathways, such as JNK activation, we used two different approaches: down-regulation of beta -catenin by Axin (Fig. 4) and inhibition of beta -catenin-Tcf complex interaction by ICAT (Fig. 5). When either Axin or ICAT was induced during the period of neuronal differentiation, the expression of the neuron-specific marker beta III-tubulin was clearly reduced, although the effect of ICAT was weaker (5.2-fold reduction in Axin induction versus 2.3-fold reduction in ICAT induction, Figs. 4 and 5). This may be due to the relatively high level of endogenous ICAT (data not shown), which could reduce the impact of induced ICAT expression. In any case, the results support the conclusion that at least part of the activity of Axin is due to its effects on the beta -catenin pathway.

In addition to the inhibition experiments, we used Wnt-3A-conditioned media to confirm that Wnt/beta -catenin signaling has a positive role in neuronal differentiation. Although the results were consistent with such an effect, we cannot rule out the possibility that the enhanced expression of the neuron-specific marker beta III-tubulin was caused by other molecules secreted by the Wnt-3A-expressing cells rather than Wnt-3A itself.

Although induction of Axin during the neurite extension period (on tissue culture plates after aggregation) blocked the formation of neurite-like structures, induction of Axin during the aggregation period did not (Fig. 6). Furthermore, induction of Axin throughout the aggregation and differentiation periods did not block the initiation of differentiation (i.e. the disappearance of markers of undifferentiated cells) (Fig. 7). One possible explanation is that endogenous Axin is already highly expressed during the aggregation stage, so that induction of exogenous Axin did not further enhance the down-regulation of beta -catenin in that period. Another plausible explanation is that Wnt signaling is not involved in the initiation of differentiation. In all our experiments we compared undifferentiated versus differentiated P19 cells after aggregation, as shown in the diagram of Fig. 6. The weak level of Wnt1 expression right after aggregation (Fig. 1B, lane 2) suggests that aggregation in the presence of RA is itself sufficient to initiate differentiation stage without Wnt signaling.

The findings, that the Axin level was lower in the brains of 1-month-old postnatal mice than in 13.5 dpc mouse embryos and that the abnormal induction of Axin blocked the formation of neurite-like structures in P19 cells, suggest that Wnt signaling has a similar function in vivo. We are currently testing that possibility by using a neuron-specific promoter to direct Tet-inducible expression in transgenic mice.

    FOOTNOTES

* This study was supported by the Biomedical Brain Research Center, Ministry of Health & Welfare, Republic of Korea (Grant 01-PJ8-PG6-01NE01-0003 to E. J.) and the National Institutes of Health (to F. C.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

|| To whom correspondence may be addressed. Tel.: 822-2210-2681; Fax: 822-2210-2888; E-mail: ej70@uos.ac.kr.

** To whom correspondence may be addressed. Tel.: 822-590-2613; Fax: 822-533-3801; E-mail: ckjoo@catholic.ac.kr.

Published, JBC Papers in Press, February 4, 2003, DOI 10.1074/jbc.M300591200

    ABBREVIATIONS

The abbreviations used are: GSK-3beta , glycogen synthase kinase 3beta ; EC, embryonal carcinoma; RA, retinoic acid; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; CM, conditioned medium; PBS, phosphate-buffered saline; RT, reverse transcriptase; PMSF, phenylmethylsulfonyl fluoride; MAP2, microtubule-associated protein 2; GFP, green fluorescence protein; EGFP, enhanced GFP; CMV, cytomegalovirus; Dox, doxycycline; Tcf/LEF, T cell factor/lymphoid enhancer factor; CKI, casein kinase I; dpc, days post-coitum; rtTA, reverse tetracycline controlled transactivator; ICAT, inhibitor of beta -catenin and Tcf-4.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Cadigan, K. M., and Nusse, R. (1997) Genes Dev. 11, 3286-3305[Free Full Text]
2. Huelsken, J., and Birchmeier, W. (2001) Curr. Opin. Genet. Dev. 11, 547-553[CrossRef][Medline] [Order article via Infotrieve]
3. Polakis, P. (2000) Genes Dev. 14, 1837-1851[Free Full Text]
4. Bienz, M., and Clevers, H. (2000) Cell 103, 311-320[Medline] [Order article via Infotrieve]
5. Moon, R. T., Bowerman, B., Boutros, M., and Perrimon, N. (2002) Science 296, 1644-1646[Abstract/Free Full Text]
6. Parr, B. A., Shea, M. J., Vassileva, G., and McMahon, A. P. (1993) Development 119, 247-261[Abstract/Free Full Text]
7. Parr, B. A., and McMahon, A. P. (1994) Curr. Opin. Genet. Dev. 4, 523-528[Medline] [Order article via Infotrieve]
8. McMahon, A. P., and Bradley, A. (1990) Cell 62, 1073-1085[Medline] [Order article via Infotrieve]
9. Ikeya, M., Lee, S. M., Johnson, J. E., McMahon, A. P., and Takada, S. (1997) Nature 389, 966-970[CrossRef][Medline] [Order article via Infotrieve]
10. Hall, A. C., Lucas, F. R., and Salinas, P. C. (2000) Cell 100, 525-535[Medline] [Order article via Infotrieve]
11. Jones, S. E., and Jomary, C. (2002) Bioessays 24, 811-820[CrossRef][Medline] [Order article via Infotrieve]
12. Liu, T., DeCostanzo, A. J., Liu, X., Wang, H., Hallagan, S., Moon, R. T., and Malbon, C. C. (2001) Science 292, 1718-1722[Abstract/Free Full Text]
13. Fagotto, F., Jho, E., Zeng, L., Kurth, T., Joos, T., Kaufmann, C., and Costantini, F. (1999) J. Cell Biol. 145, 741-756[Abstract/Free Full Text]
14. Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B., and Polakis, P. (1998) Curr. Biol. 8, 573-581[Medline] [Order article via Infotrieve]
15. Hsu, W., Zeng, L., and Costantini, F. (1999) J. Biol. Chem. 274, 3439-3445[Abstract/Free Full Text]
16. Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S., and Kikuchi, A. (1998) EMBO J. 17, 1371-1384[Abstract/Free Full Text]
17. Itoh, K., Krupnik, V. E., and Sokol, S. Y. (1998) Curr. Biol. 8, 591-594[Medline] [Order article via Infotrieve]
18. Julius, M. A., Schelbert, B., Hsu, W., Fitzpatrick, E., Jho, E., Fagotto, F., Costantini, F., and Kitajewski, J. (2000) Biochem. Biophys. Res. Commun. 276, 1162-1169[CrossRef][Medline] [Order article via Infotrieve]
19. Kishida, S., Yamamoto, H., Hino, S., Ikeda, S., Kishida, M., and Kikuchi, A. (1999) Mol. Cell. Biol. 19, 4414-4422[Abstract/Free Full Text]
20. Kishida, S., Yamamoto, H., Ikeda, S., Kishida, M., Sakamoto, I., Koyama, S., and Kikuchi, A. (1998) J. Biol. Chem. 273, 10823-10826[Abstract/Free Full Text]
21. Li, L., Yuan, H., Weaver, C. D., Mao, J., Farr, G. H., 3rd, Sussman, D. J., Jonkers, J., Kimelman, D., and Wu, D. (1999) EMBO J. 18, 4233-4240[Abstract/Free Full Text]
22. Nakamura, T., Hamada, F., Ishidate, T., Anai, K., Kawahara, K., Toyoshima, K., and Akiyama, T. (1998) Genes Cells 3, 395-403[Abstract/Free Full Text]
23. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X., and He, X. (2002) Cell 108, 837-847[Medline] [Order article via Infotrieve]
24. Sakanaka, C., Leong, P., Xu, L., Harrison, S. D., and Williams, L. T. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 12548-12552[Abstract/Free Full Text]
25. Smalley, M. J., Sara, E., Paterson, H., Naylor, S., Cook, D., Jayatilake, H., Fryer, L. G., Hutchinson, L., Fry, M. J., and Dale, T. C. (1999) EMBO J. 18, 2823-2835[Abstract/Free Full Text]
26. Hart, M., Concordet, J. P., Lassot, I., Albert, I., del los Santos, R., Durand, H., Perret, C., Rubinfeld, B., Margottin, F., Benarous, R., and Polakis, P. (1999) Curr. Biol. 9, 207-210[CrossRef][Medline] [Order article via Infotrieve]
27. Kitagawa, M., Hatakeyama, S., Shirane, M., Matsumoto, M., Ishida, N., Hattori, K., Nakamichi, I., Kikuchi, A., and Nakayama, K. (1999) EMBO J. 18, 2401-2410[Abstract/Free Full Text]
28. Latres, E., Chiaur, D. S., and Pagano, M. (1999) Oncogene 18, 849-854[CrossRef][Medline] [Order article via Infotrieve]
29. Liu, C., Kato, Y., Zhang, Z., Do, V. M., Yankner, B. A., and He, X. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6273-6278[Abstract/Free Full Text]
30. Winston, J. T., Strack, P., Beer-Romero, P., Chu, C. Y., Elledge, S. J., and Harper, J. W. (1999) Genes Dev. 13, 270-283[Abstract/Free Full Text]
31. Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and Birchmeier, W. (1996) Nature 382, 638-642[CrossRef][Medline] [Order article via Infotrieve]
32. Huber, O., Korn, R., McLaughlin, J., Ohsugi, M., Herrmann, B. G., and Kemler, R. (1996) Mech. Dev. 59, 3-10[CrossRef][Medline] [Order article via Infotrieve]
33. Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destree, O., and Clevers, H. (1996) Cell 86, 391-399[Medline] [Order article via Infotrieve]
34. Eastman, Q., and Grosschedl, R. (1999) Curr. Opin. Cell Biol. 11, 233-240[CrossRef][Medline] [Order article via Infotrieve]
35. Gluecksohn-Schoenheimer, S. (1949) J. Exp. Zool. 110, 47-76
36. Perry, W. L., 3rd, Vasicek, T. J., Lee, J. J., Rossi, J. M., Zeng, L., Zhang, T., Tilghman, S. M., and Costantini, F. (1995) Genetics 141, 321-332[Abstract/Free Full Text]
37. Zeng, L., Fagotto, F., Zhang, T., Hsu, W., Vasicek, T. J., Perry, W. L., 3rd, Lee, J. J., Tilghman, S. M., Gumbiner, B. M., and Costantini, F. (1997) Cell 90, 181-192[Medline] [Order article via Infotrieve]
38. Hamada, F., Tomoyasu, Y., Takatsu, Y., Nakamura, M., Nagai, S., Suzuki, A., Fujita, F., Shibuya, H., Toyoshima, K., Ueno, N., and Akiyama, T. (1999) Science 283, 1739-1742[Abstract/Free Full Text]
39. Willert, K., Logan, C. Y., Arora, A., Fish, M., and Nusse, R. (1999) Development 126, 4165-4173[Abstract/Free Full Text]
40. Jho, E., Lomvardas, S., and Costantini, F. (1999) Biochem. Biophys. Res. Commun. 266, 28-35[CrossRef][Medline] [Order article via Infotrieve]
41. Willert, K., Shibamoto, S., and Nusse, R. (1999) Genes Dev. 13, 1768-1773[Abstract/Free Full Text]
42. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., and Kinzler, K. W. (1998) Science 281, 1509-1512[Abstract/Free Full Text]
43. Tetsu, O., and McCormick, F. (1999) Nature 398, 422-426[CrossRef][Medline] [Order article via Infotrieve]
44. Brannon, M., Gomperts, M., Sumoy, L., Moon, R. T., and Kimelman, D. (1997) Genes Dev. 11, 2359-2370[Abstract/Free Full Text]
45. Yamaguchi, T. P., Takada, S., Yoshikawa, Y., Wu, N., and McMahon, A. P. (1999) Genes Dev. 13, 3185-3190[Abstract/Free Full Text]
46. Muroyama, Y., Fujihara, M., Ikeya, M., Kondoh, H., and Takada, S. (2002) Genes Dev. 16, 548-553[Abstract/Free Full Text]
47. McBurney, M. W., Jones-Villeneuve, E. M., Edwards, M. K., and Anderson, P. J. (1982) Nature 299, 165-167[Medline] [Order article via Infotrieve]
48. McBurney, M. W. (1993) Int. J. Dev. Biol. 37, 135-140[Medline] [Order article via Infotrieve]
49. Smolich, B. D., and Papkoff, J. (1994) Dev. Biol. 166, 300-310[CrossRef][Medline] [Order article via Infotrieve]
50. Tang, K., Yang, J., Gao, X., Wang, C., Liu, L., Kitani, H., Atsumi, T., and Jing, N. (2002) Biochem. Biophys. Res. Commun. 293, 167-173[CrossRef][Medline] [Order article via Infotrieve]
51. Gossen, M., Freundlieb, S., Bender, G., Muller, G., Hillen, W., and Bujard, H. (1995) Science 268, 1766-1769[Medline] [Order article via Infotrieve]
52. Urlinger, S., Baron, U., Thellmann, M., Hasan, M. T., Bujard, H., and Hillen, W. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 7963-7968[Abstract/Free Full Text]
53. Tago, K., Nakamura, T., Nishita, M., Hyodo, J., Nagai, S., Murata, Y., Adachi, S., Ohwada, S., Morishita, Y., Shibuya, H., and Akiyama, T. (2000) Genes Dev. 14, 1741-1749[Abstract/Free Full Text]
54. Yamamoto, H., Kishida, S., Kishida, M., Ikeda, S., Takada, S., and Kikuchi, A. (1999) J. Biol. Chem. 274, 10681-10684[Abstract/Free Full Text]
55. Kusek, J. C., Greene, R. M., and Pisano, M. M. (2001) Brain Res. Bull. 54, 187-198[CrossRef][Medline] [Order article via Infotrieve]
56. Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T., Ishiguro, H., Fujita, M., Tokino, T., Sasaki, Y., Imaoka, S., Murata, M., Shimano, T., Yamaoka, Y., and Nakamura, Y. (2000) Nat. Genet. 24, 245-250[CrossRef][Medline] [Order article via Infotrieve]
57. Hsu, W., Shakya, R., and Costantini, F. (2001) J. Cell Biol. 155, 1055-1064[Abstract/Free Full Text]
58. Graham, T. A., Clements, W. K., Kimelman, D., and Xu, W. (2002) Mol. Cell 10, 563-571[Medline] [Order article via Infotrieve]
59. Gao, X., Bian, W., Yang, J., Tang, K., Kitani, H., Atsumi, T., and Jing, N. (2001) Biochem. Biophys. Res. Commun. 284, 1098-1103[CrossRef][Medline] [Order article via Infotrieve]
60. Jho, E. H., and Malbon, C. C. (1997) J. Biol. Chem. 272, 24461-24467[Abstract/Free Full Text]
61. Lisman, J., Schulman, H., and Cline, H. (2002) Nat. Rev. Neurosci. 3, 175-190[CrossRef][Medline] [Order article via Infotrieve]
62. Dunn, K. J., Williams, B. O., Li, Y., and Pavan, W. J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10050-10055[Abstract/Free Full Text]
63. Petropoulos, H., and Skerjanc, I. S. (2002) J. Biol. Chem. 277, 15393-15399[Abstract/Free Full Text]
64. Neo, S. Y., Zhang, Y., Yaw, L. P., Li, P., and Lin, S. C. (2000) Biochem. Biophys. Res. Commun. 272, 144-150[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.